The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners
Latest from The University of Texas MD Anderson Cancer Center
Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.
James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
